Literature DB >> 10483582

From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of Thymic Epithelial Tumors and related recent developments.

A Marx, H K Müller-Hermelink.   

Abstract

The Second Conference on Biological and Clinical Aspects of Thymic Epithelial Tumors in Leiden, The Netherlands, 1998, set the stage for an interdisciplinary meeting of immunologists, pathologists and members of various clinical disciplines to exchange their recent findings in the field of thymus-related biology, pathology, and medicine. The contributions covered such diverse subjects as the role of transcription factors and cytokines in the development of the thymic microenvironment, thymic T, B and NK cell development, the pathogenesis of myasthenia gravis and other thymoma-associated autoimmunities, the pathology of thymic epithelial tumors and germ cell neoplasms, and new approaches to their diagnosis and treatment. This editorial will briefly sum up the data presented at the Conference and will comment on related novel findings that have been reported since then. Because it was also at the Leiden Conference, that the proposal of the WHO committee for the classification of thymic tumors was discussed for the first time, a description of the upcoming WHO Classification of Tumors of the Thymus is given with emphasis on the diagnostic criteria of thymic epithelial tumors, that should now be termed as type A, AB, B1-3 and type C thymomas, to make pathological and clinical studies comparable in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483582     DOI: 10.1016/s0344-0338(99)80001-6

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

1.  Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin's disease.

Authors:  M T Ferrò; T Riccardi; A Montanelli; P Bernasconi; R Mantegazza
Journal:  J Neurol       Date:  2006-09-29       Impact factor: 4.849

2.  World Health Organization type B2 thymoma with an abundance of Hassall's corpuscles: A case report.

Authors:  Li Gong; Lu Sun; Chenling Zhang; Sanhua Wei; Jun Chen; Yazhuo Li; Yanhong Li; Wei Zhang; Yongsheng Zhang
Journal:  Oncol Lett       Date:  2018-04-11       Impact factor: 2.967

3.  Thymic epithelial tumors can develop along two different pathogenetic pathways.

Authors:  R Zhou; A Zettl; P Ströbel; K Wagner; H K Müller-Hermelink; S Zhang; A Marx; P Starostik
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Cytoplasm estrogen receptor β5 as an improved prognostic factor in thymoma and thymic carcinoma progression.

Authors:  Sheng-Ying Li; Yu-Xia Wang; Lei Wang; Zhi-Bing Qian; Ming-Li Ji
Journal:  Oncol Lett       Date:  2015-07-30       Impact factor: 2.967

5.  Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution.

Authors:  Pia Bernasconi; Massimo Barberis; Fulvio Baggi; Laura Passerini; Maria Cannone; Elisa Arnoldi; Lorenzo Novellino; Ferdinando Cornelio; Renato Mantegazza
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

6.  Recurrent genetic aberrations in thymoma and thymic carcinoma.

Authors:  A Zettl; P Ströbel; K Wagner; T Katzenberger; G Ott; A Rosenwald; K Peters; A Krein; M Semik; H K Müller-Hermelink; A Marx
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  Spontaneous mediastinal haemorrhage linked with thymic carcinoma and myelodysplasia: a case report.

Authors:  Suresh R Fernando; Filip Van Tornout; Richard Y Ball; Jennie Z Wimperis
Journal:  Cases J       Date:  2009-06-09

8.  [Polymyositis associated with thymoma].

Authors:  B Jordan; K Eger; S Zierz
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

9.  Protein expression status of p53 and epidermal growth factor receptor in thymoma.

Authors:  Fei Cui; Jianxing He; Jun Liu; Yijiang Chen
Journal:  Oncol Lett       Date:  2011-03-14       Impact factor: 2.967

10.  Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.

Authors:  A Meager; M Wadhwa; P Dilger; C Bird; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.